Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vbi Vaccines Inc CS (NQ: VBIV )

0.3148 -0.0053 (-1.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 693,515
Open 0.3219
Bid (Size) 0.3080 (2)
Ask (Size) 0.3289 (8)
Prev. Close 0.3201
Today's Range 0.3081 - 0.3490
52wk Range 0.2350 - 1.860
Shares Outstanding 258,257,494
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 74 companies achieved new lows for the year. 
Via Benzinga
VBI Vaccines Earnings Perspective: Return On Capital Employed
 
Via Benzinga

Performance

YTD
-26.64%
-26.64%
1 Month
-35.09%
-35.09%
3 Month
-16.28%
-16.28%
6 Month
-59.76%
-59.76%
1 Year
-81.91%
-81.91%

More News

Read More
VBI Vaccines Reports Full Year 2022 Financial Results
From VBI Vaccines Inc.
Via Business Wire
Looking Into VBI Vaccines's Return On Capital Employed
Via Benzinga
VBI Vaccines, Agenus Ink Partnership For Combination Brain Cancer Therapy
Via Benzinga
VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
From VBI Vaccines Inc.
Via Business Wire
Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults
From VBI Vaccines Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal
From VBI Vaccines Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in Upcoming Investor Conferences
From VBI Vaccines Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2022
Via Benzinga
VBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
From Agenus Inc.
Via Globe NewsWire
VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting
From VBI Vaccines Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.